Evidence map›Paper›PMID 33208054›Full record

ArticleVeterinary pathology2021

Development of Mast Cell and Eosinophil Hyperplasia and HLH/MAS-Like Disease in NSG-SGM3 Mice Receiving Human CD34+ Hematopoietic Stem Cells or Patient-Derived Leukemia Xenografts.

Laura J Janke, Denise M Imai, Heather Tillman, Rosalinda Doty, Mark J Hoenerhoff, Jiajie J Xu, Zachary T Freeman, Portia Allen, Natalie Wall Fowlkes, Ilaria Iacobucci and 4 more

Open access · greenAbstract read
In one paragraph

Article in Veterinary pathology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 35 citations in OpenAlex.

  1. Humanized immune system animal models and their recent applications.Animal models and experimental medicine · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Murine Models of Secondary Cytokine Storm Syndromes.Advances in experimental medicine and biology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 1 country.

Laura J Janke5417St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID 0000-0002-9871-6239
Denise M Imai8789University of California, Davis, CA, USA.ORCID 0000-0003-0667-2054
Heather Tillman5417St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID 0000-0002-9623-2812
Rosalinda Doty1514The Jackson Laboratory, Bar Harbor, ME, USA.
Mark J Hoenerhoff12266University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0003-0070-5900
Jiajie J Xu12266University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0003-0910-7376
Zachary T Freeman12266University of Michigan, Ann Arbor, MI, USA.
Portia Allen12266University of Michigan, Ann Arbor, MI, USA.
Natalie Wall Fowlkes4002The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-7711-6031
Ilaria Iacobucci5417St. Jude Children's Research Hospital, Memphis, TN, USA.
Kirsten Dickerson5417St. Jude Children's Research Hospital, Memphis, TN, USA.
Charles G Mullighan5417St. Jude Children's Research Hospital, Memphis, TN, USA.
Peter Vogel5417St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID 0000-0002-7535-0545
Jerold E Rehg5417St. Jude Children's Research Hospital, Memphis, TN, USA.
St. Jude Children's Research Hospital · USUniversity of Michigan · USJackson Laboratory · USThe University of Texas MD Anderson Cancer Center · USUniversity of California, Davis · US

Funding

Viral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CHARLES ROBERTS · 1985 to 2026
$166.9M
Translating genomic discoveries to improved outcomes for high risk acute leukemiaR35CA197695 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Charles G Mullighan · 2017 to 2026
$11.4M
NCI NIH HHS P30 CA021765NCI NIH HHS R35 CA197695
6 · The paper itself

Abstract

Immunocompromised mouse strains expressing human transgenes are being increasingly used in biomedical research. The genetic modifications in these mice cause various cellular responses, resulting in histologic features unique to each strain. The NSG-SGM3 mouse strain is similar to the commonly used NSG (NOD

Indexed as

Hematopoietic Stem Cell TransplantationLeukemiaLymphohistiocytosis, HemophagocyticMacrophage Activation SyndromeAnimalsEosinophilsHematopoietic Stem CellsHeterograftsHumansHyperplasiaMast CellsMiceMice, Inbred NODMice, SCIDeosinophil hyperplasiahemophagocytic lymphohistiocytosismacrophage activation syndromemast cell hyperplasiaNSGNSG-SGM3

Identifiers

PMID33208054
PMCPMC8414369
OpenAlexW3104704485

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.